Global Times: Clay Figure Zhang’s works naturally reflect spiritual state of the times
BEIJING, Dec. 7, 2024 /PRNewswire/ — From exquisite craftsmanship to traditional Chinese medicine, from solemn rituals to vibrant folk art, intangible cultural heritage weaves the tapestry of Chinese identity. For centuries, the essential elements of intangible cultural heritage have been pass
University of Nebraska Wins the Abbott and Big Ten Conference’s Nationwide ‘We Give Blood Drive’ Competition, Receives $1 Million Grant from Abbott
Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide competition this college football season, helping save as many as 60,000 lives Nebraska’s win was announced at the Discover Big Ten Football Championship Game where the uni
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 7, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating fixed-duration investigational epcoritam
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML – – 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to pr
Media Advisory -Prime Minister’s itinerary for Sunday, December 8, 2024
OTTAWA, ON, Dec. 7, 2024 /CNW/ – National Capital Region, Canada No public events scheduled This document is also available at https://pm.gc.ca SOURCE Prime Minister’s Office
New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients
ROTTERDAM, the Netherlands and SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announce that groundbreaking data on the Prognostic Valu
MosquitoMate receives first Vector Expedited Review Voucher (VERV) from the US Environmental Protection Agency
LEXINGTON, Ky., Dec. 7, 2024 /PRNewswire/ — The US Environmental Protection Agency (EPA) has just announced MosquitoMate as its first awardee in a new effort to fight the growing crisis of mosquito transmitted diseases. To help address the growing problem, in 2022 Congress mandated that the EP
Building Homes for Heroes Gifts 400th Home, Marking Historic Achievement in Veteran and First Responder Support
Building Homes for Heroes & Hillwood Properties partner to gift milestone home in Dallas, Texas NEW YORK, Dec. 7, 2024 /PRNewswire/ — Building Homes for Heroes today marked a transformative milestone with the gifting of its 400th home to U.S. Army Specialist Joshua Sager and his family in
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a 50.7% Objective Response Rate (ORR), 23.0-month Median Duration of Response (DOR), and Median Overall Survival (OS) of 18.4 months Safety findings consistent with prior studies with no reports of cytokine release syndro
Blueprint Medicines’ Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
— ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM — — Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT — CAMBRIDGE, Mass., Dec. 7, 2024 /PRNewswire/ —
